Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19935697 
Humtsoe JO, Kramer RH (2010) Differential epidermal growth factor receptor signaling regulates anchorage-independent growth by modulation of the PI3K/AKT pathway. Oncogene 29, 1214-26 19935697
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  liver cancer, squamous cell carcinoma of the liver
 Relevant cell lines - cell types - tissues:  HSC (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase cells in multicellular aggregates
PD168393 serum inhibit treatment-induced increase
AG1478 serum inhibit treatment-induced increase
EGF increase

Y869-p - EGFR (human)
Orthologous residues
EGFR (human): Y869‑p, EGFR iso5 (human): Y869‑p, EGFR (mouse): Y871‑p, EGFR (rat): Y870‑p, EGFR (pig): Y869‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  liver cancer, squamous cell carcinoma of the liver
 Relevant cell lines - cell types - tissues:  HSC (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE EGFR (human) transfection of wild-type enzyme EGFR autophosphorylation, Y1110 is inefficiently autophosphorylated in aggregated cells
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase multicellular aggregates
serum increase multicellular aggregates
PD168393 serum inhibit treatment-induced increase
AG1478 serum inhibit treatment-induced increase
EGTA no change compared to control
Ca(2+) increase
cell adhesion increase hE-Cadherin/Fc beads

Y1092-p - EGFR (human)
Orthologous residues
EGFR (human): Y1092‑p, EGFR iso5 (human): , EGFR (mouse): Y1092‑p, EGFR (rat): Y1091‑p, EGFR (pig): Y1091‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  liver cancer, squamous cell carcinoma of the liver
 Relevant cell lines - cell types - tissues:  HSC (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase multicellular aggregates
serum increase multicellular aggregates
PD168393 serum inhibit treatment-induced increase
AG1478 serum inhibit treatment-induced increase
EGTA no change compared to control
Ca(2+) increase
cell adhesion increase hE-Cadherin/Fc beads

Y1110-p - EGFR (human)
Orthologous residues
EGFR (human): Y1110‑p, EGFR iso5 (human): , EGFR (mouse): Y1110‑p, EGFR (rat): Y1109‑p, EGFR (pig): Y1109‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  liver cancer, squamous cell carcinoma of the liver
 Relevant cell lines - cell types - tissues:  HSC (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE EGFR (human) transfection of wild-type enzyme EGFR autophosphorylation, Y1110 is inefficiently autophosphorylated in aggregated cells
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
no change compared to control multicellular aggregates
serum increase
PD168393 serum inhibit treatment-induced increase
AG1478 serum inhibit treatment-induced increase
EGTA no change compared to control
Ca(2+) no change compared to control
IL2RA (human) no change compared to control wild-type
EGFR (human) increase wild-type
EGFR (human), CDH1 (human) no change compared to control EGFR WT + E-cadherin construct
cell adhesion no change compared to control HE-cadherin/Fc beads

Y1172-p - EGFR (human)
Orthologous residues
EGFR (human): Y1172‑p, EGFR iso5 (human): , EGFR (mouse): Y1172‑p, EGFR (rat): Y1171‑p, EGFR (pig): Y1171‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  liver cancer, squamous cell carcinoma of the liver
 Relevant cell lines - cell types - tissues:  HSC (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE EGFR (human) transfection of wild-type enzyme EGFR autophosphorylation, Y1110 is inefficiently autophosphorylated in aggregated cells
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase multicellular aggregates
serum increase multicellular aggregates
PD168393 serum inhibit treatment-induced increase
AG1478 serum inhibit treatment-induced increase
EGTA no change compared to control
Ca(2+) increase
cell adhesion increase hE-Cadherin/Fc beads

Y1197-p - EGFR (human)
Orthologous residues
EGFR (human): Y1197‑p, EGFR iso5 (human): , EGFR (mouse): Y1197‑p, EGFR (rat): Y1196‑p, EGFR (pig): Y1196‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  liver cancer, squamous cell carcinoma of the liver
 Relevant cell lines - cell types - tissues:  HSC (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE EGFR (human) transfection of wild-type enzyme EGFR autophosphorylation, Y1110 is inefficiently autophosphorylated in aggregated cells
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase multicellular aggregates
serum increase multicellular aggregates
PD168393 serum inhibit treatment-induced increase
AG1478 serum inhibit treatment-induced increase
EGTA no change compared to control
Ca(2+) increase
cell adhesion increase hE-Cadherin/Fc beads

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  liver cancer, squamous cell carcinoma of the liver
 Relevant cell lines - cell types - tissues:  HSC (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum no change compared to control multicellular aggregates
EGF increase
IL2RA (human) increase IL2RA-EGFR chimera
serum increase cells in multicellular aggregates
PD168393 serum inhibit treatment-induced increase
AG1478 serum inhibit treatment-induced increase
EGF increase

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  liver cancer, squamous cell carcinoma of the liver
 Relevant cell lines - cell types - tissues:  HSC (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum no change compared to control multicellular aggregates
EGF increase
IL2RA (human) increase IL2RA-EGFR chimera
serum increase cells in multicellular aggregates
PD168393 serum inhibit treatment-induced increase
AG1478 serum inhibit treatment-induced increase
EGF increase

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  liver cancer, squamous cell carcinoma of the liver
 Relevant cell lines - cell types - tissues:  HSC (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum no change compared to control multicellular aggregates
EGF increase
IL2RA (human) increase IL2RA-EGFR chimera
serum increase cells in multicellular aggregates
PD168393 serum inhibit treatment-induced increase
AG1478 serum inhibit treatment-induced increase
EGF increase

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  liver cancer, squamous cell carcinoma of the liver
 Relevant cell lines - cell types - tissues:  HSC (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum no change compared to control multicellular aggregates
EGF increase
IL2RA (human) increase IL2RA-EGFR chimera
serum increase cells in multicellular aggregates
PD168393 serum inhibit treatment-induced increase
AG1478 serum inhibit treatment-induced increase
EGF increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.